NCT07050160View on ClinicalTrials.gov

Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant

Not yet recruitingOBSERVATIONAL

Enrollment

10

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

August 31, 2030

Study Completion Date

August 31, 2030

Conditions

Arrhythmogenic CardiomyopathyPKP2-ACMPKP2-ARVC

Sponsors

Lead Sponsor

Lexeo Therapeutics

All Listed Sponsors

lead

Lexeo Therapeutics

INDUSTRY